Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2/3 · Active, not recruiting · Enrollment 1003

NCT06921486

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Phase IIb:Efsubaglutide Alfa 5 mg QWn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 10 mg QWn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg QWn/rn/rn/rn/r
Phase IIb:Efsubaglutide Alfa 20 mg Q2Wn/rn/rn/rn/r
Phase IIb:Placebon/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QWn/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose QWn/rn/rn/rn/r
Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2Wn/rn/rn/rn/r
Phase III:Placebon/rn/rn/rn/r

Not shown

  • Phase IIb:Efsubaglutide Alfa 5 mg QW: endpoint not reported
  • Phase IIb:Efsubaglutide Alfa 10 mg QW: endpoint not reported
  • Phase IIb:Efsubaglutide Alfa 20 mg QW: endpoint not reported
  • Phase IIb:Efsubaglutide Alfa 20 mg Q2W: endpoint not reported
  • Phase IIb:Placebo: endpoint not reported
  • Phase III:Recommended Phase 3 Dose (RP3D) Low Dose QW: endpoint not reported
  • Phase III:Recommended Phase 3 Dose (RP3D) High Dose QW: endpoint not reported
  • Phase III:Recommended Phase 3 Dose (RP3D) High Dose Q2W: endpoint not reported
  • Phase III:Placebo: endpoint not reported